● Recruiting

A Phase III Study of SHR-8068 in Combination With Adebrelimab and Platinum-Containing Chemotherapy Versus Durvalumab in Combination With Platinum-Containing Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer (BTC)

Condition: Advanced Biliary Tract Cancer · Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.

PhasePhase 3

Planned participants604

Who can joinAll sexes, 18 Years to 75 Years

Healthy volunteersNo

About this study

This study is a randomized, open-label, multicenter phase III clinical trial, aiming to evaluate the efficacy and safety of SHR-8068 combined with adbelimab and platinum-based chemotherapy in contrast to varicumab combined with platinum-based chemotherapy in the first-line treatment of patients with advanced BTC.

This description comes directly from the study's public registry record.

Talk to the study team

Xin Shi · +86-0518-82342973 · xin.shi.xs3@hengrui.com

Xin Xu · +86-0518-82342973 · xin.xu@hengrui.com

Always discuss trial participation with your own doctor first.

Locations (1)

The First Affiliated Hospital, College of Medicine, Zhejiang University

Hangzhou, Zhejiang, China

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07229625